Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor

Blood

Volumn 105, Issue 4, 2005, Pages 1531-1539

  Hough, Christine ^a   Cuthbert, Carla D ^a   Notley, Colleen ^a   Brown, Christine ^a   Hegadorn, Carol ^a   Berber, Ergul ^a   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NUCLEOTIDE; PROTEIN E4BP4; REPRESSOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CELL TYPE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION ANALYSIS; CONTROLLED STUDY; DNA BINDING; DNA RESPONSIVE ELEMENT; E4BP4 GENE; ENDOTHELIUM CELL; GENE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; REGULATOR GENE; REPRESSOR GENE; VWF GENE;

EID: 13544257126     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3093     Document Type: Article

References (49)

1. Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985;76:1102-1106.
2. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52:2757-2764.
3. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol. 1989;108:1283-1289.
4. Meyer D, Girma JP. von Willebrand factor: structure and function. Thromb Haemost. 1993;70:99-104.
5. Meyer D, Pietu G, Fressinaud E, Girma JP. von Willebrand factor: structure and function. Mayo Clin Proc. 1991;66:516-523.
6. Girma JP, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationship of human von Willebrand factor. Blood. 1987;70:605-611.
7. Ruggeri ZM. Structure and function of von Willebrand factor: relationship to von Willebrand's disease. Mayo Clin Proc. 1991;66:847-861.
8. Badimon L, Badimon JJ, Chesebro JH, Fuster V. von Willebrand factor and cardiovascular disease. Thromb Haemost. 1993;70:111-118.
9. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691-1695.
10. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol. 1997;138:1117-1124.
11. Aird WC, Jahroudi N, Weiler-Guettler H, Rayburn HB, Rosenberg RD. Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci USA. 1995;92:4567-4571.
12. Wu QY, Drouet L, Carrier JL, et al. Differential distribution of von Willebrand factor in endothelial cells: comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis. 1987;7:47-54.
13. Nagel T, Resnick N, Dewey CF Jr, Gimbrone MA Jr. Vascular endothelial cells respond to spatial gradients in fluid shear stress by enhanced activation of transcription factors. Arterioscler Thromb Vasc Biol. 1999;19:1825-1834.
14. Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood. 1999;93:4277-4283.
15. Ferreira V, Assouline Z, Schwachtgen JL, Bahnak BR, Meyer D, Kerbiriou-Nabias D. The role of the 5′-flanking region in the cell-specific transcription of the human von Willebrand factor gene. Biochem J. 1993;293(pt 3):641-648.
16. Guan J, Guillot PV, Aird WC. Characterization of the mouse von Willebrand factor promoter. Blood. 1999;94:3405-3412.
17. Janel N, Schwachtgen JL, Bakhshi MR, Barek L, Meyer D, Kerbiriou-Nabias D. Comparison of the 5′-flanking sequences of the human and bovine von Willebrand factor-encoding genes reveals alternation of highly homologous domains with species-specific Alu-type repeats. Gene. 1995;167:291-295.
18. Jahroudi N, Lynch DC. Endothelial-cell-specific regulation of von Willebrand factor gene expression. Mol Cell Biol. 1994;14:999-1008.
19. Ardekani AM, Greenberger JS, Jahroudi N. Two repressor elements inhibit expression of the von Willebrand factor gene promoter in vitro. Thromb Haemost. 1998;80:488-494.
20. Jahroudi N, Ardekani AM, Greenberger JS. An NF1-like protein functions as a repressor of the von Willebrand factor promoter. J Biol Chem. 1996;271;21413-21421.
21. Schwachtgen JL, Janel N, Barek L, et al. Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene. Oncogene. 1997;15:3091-3102.
22. Cuthbert CD. Expression of Von Willebrand Factor: Transcriptional Regulatory Control and the Influence of Inflammation [PhD thesis/dissertation]. Queen's University, Kingston, ON, Canada; 2000:58-80.
23. Schwachtgen JL, Remade JE, Janel N, et al. Oct-1 is involved in the transcriptional repression of the von Willebrand factor gene promoter. Blood. 1998;92:1247-1258.
24. Peng Y, Jahroudi N. The NFY transcription factor functions as a repressor and activator of the von Willebrand factor promoter. Blood. 2002;99:2408-2417.
25. Peng Y, Jahroudi N. The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. J Biol Chem. 2003;278:8385-8394.
26. Minami T, Donovan DJ, Tsai JC, Rosenberg RD, Aird WC. Differential regulation of the von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine phosphoribosyltransferase-targeted mice. Blood. 2002;100:4019-4025.
27. Wilhide CC, Van Dang C, Dipersio J, Kenedy AA, Bray PF. Overexpression of cyclin D1 in the Dami megakaryocytic cell line causes growth arrest. Blood. 1995;86:294-304.
28. Gimbrone MA Jr. Culture of vascular endothelium. Prog Hemost Thromb. 1976;3:1-28.
29. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456-467.
30. Dignam JD. Preparation of extracts from higher eukaryotes. Methods Enzymol. 1990;182:194-203.
31. Sierra FA. A Laboratory Guide to In Vitro Transcription. Basel, Switzerland: Verlag; 1990.
32. Cowell IG, Hurst HC. Transcriptional repression by the human bZIP factor E4BP4: definition of a minimal repression domain. Nucleic Acids Res. 1994;22:59-65.
33. Cowell IG. E4BP4/NFIL3, a PAR-related bZIP factor with many roles. Bioessays. 2002;24:1023-1029.
34. Lai CK, Ting LP. Transcriptional repression of human hepatitis B virus genes by a bZIP family member, E4BP4. J Virol. 1999;73:3197-3209.
35. Chen WJ, Lewis KS, Chandra G, et al. Characterization of human E4BP4, a phosphorylated bZIP factor. Biochim Biophys Acta. 1995;1264:388-396.
36. Greenberg SM, Rosenthal DS, Greeley TA, Tantravahi R, Handin RI. Characterization of a new megakaryocytic cell line: the Dami cell. Blood. 1988;72:1968-1977.
37. Deveaux S, Filipe A, Lemarchandel V, Ghysdael J, Romeo PH, Mignotte V. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood. 1996;87:4678-4685.
38. Lemarchandel V, Ghysdael J, Mignotte V, Rahuel C, Romeo PH. GATA and Ets cis-acting sequences mediate megakaryocyte-specific expression. Mol Cell Biol. 1993;13:668-676.
39. Okabe M, Kunieda Y, Shoji M, et al. Megakaryocytic differentiation of a leukemic cell line, MC3, by phorbol ester: induction of glycoprotein IIb/IIIa and effects on expression of IL-6, IL-6 receptor, mpl and GATA genes. Leuk Res. 1995;19:933-943.
40. Ravid K, Doi T, Beeler DL, Kuter DJ, Rosenberg RD. Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site. Mol Cell Biol. 1991;11:6116-6127.
41. Prandini MH, Martin F, Thevenon D, Uzan G. The tissue-specific transcriptional regulation of the megakaryocytic glycoprotein lib gene is controlled by interactions between a repressor and positive cis-acting elements. Blood. 1996;88:2062-2070.
42. Bastian LS, Yagi M, Chan C, Roth GJ. Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites. J Biol Chem. 1996;271:18554-18560.
43. Minami T, Tachibana K, Imanishi T, Doi T. Both Ets-1 and GATA-1 are essential for positive regulation of platelet factor 4 gene expression. Eur J Biochem. 1998;258:879-889.
44. Cowell IG, Hurst HC. Protein-protein interaction between the transcriptional repressor E4BP4 and the TBP-binding protein Dr1. Nucleic Acids Res. 1996;24:3607-3613.
45. Mermelstein F, Yeung K, Cao J, et al. Requirement of a corepressor for Dr1-mediated repression of transcription. Genes Dev. 1996;10:1033-1048.
46. Inostroza JA, Mermelstein FH, Ha I, Lane WS, Reinberg D. Dr1, a TATA-binding protein-associated phosphoprotein and inhibitor of class II gene transcription. Cell. 1992;70:477-489.
47. Cowell IG, Skinner A, Hurst HC. Transcriptional repression by a novel member of the bZIP family of transcription factors. Mol Cell Biol. 1992;12:3070-3077.
48. Doi M, Okano T, Yujnovsky I, Sassone-Corsi P, Fukada Y. Negative control of circadian clock regulator E4BP4 by casein kinase lepsilon-mediated phosphorylation. Curr Biol. 2004;14:975-980.
49. Wallace AD, Wheeler TT, Young DA. Inducibility of E4BP4 suggests a novel mechanism of negative gene regulation by glucocorticoids. Biochem Biophys Res Commun. 1997;232:403-406.